ENTA enanta.com: Rasio rega marang prakiraan pendapatan

Logo perusahaan publik Enanta Pharmaceuticals Inc. (ENTA)

Effective management at Enanta Pharmaceuticals (ENTA) ensures R&D transparency and strict cost control. The prospects for new antiviral combinations are only beginning to emerge, as confirmed by the forward price-to-sales valuation, where the metric value is 4.90. However, low cash flow predictability due to irregular royalties makes cash generation unstable, creating risks for the long-term sustainability of the business.

Enanta Pharmaceuticals, Inc. - Multiplikator Forward P/S ENTA (periode 04.07.2022 - 15.11.2026)

Rincian analitis perusahaan Enanta Pharmaceuticals (ENTA)

- rega saiki lan proyeksi nilai saham:
Rega saham enanta.com|ENTA - Rata-rata rega prakiraan
- data kapitalisasi saham perusahaan:
Nilai pasar Enanta|ENTA - Nilai Bisnis
- indikator nilai buku ekuitas:
Nilai Buku saben Saham Enanta Pharmaceuticals|ENTA - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku enanta.com|ENTA - Total Aset Bisnis
- indikator total utang lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas Enanta Pharmaceuticals|ENTA - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal enanta.com|ENTA - Gunggung utang perusahaan|Utang marang nilai buku Enanta Pharmaceuticals Inc.|ENTA - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Enanta Pharmaceuticals|Rasio cepet enanta.com
- rincian asil keuangan lan kelipatan valuasi:
ENTA - Bathi pungkasan|Proyeksi bathi mangsa ngarep Enanta Pharmaceuticals|ENTA - Pangali P/E|Rega marang bathi mangsa ngarep Enanta Pharmaceuticals|ENTA - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Enanta Pharmaceuticals Inc.|ENTA - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Enanta Pharmaceuticals|ENTA - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan enanta.com|ENTA - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Enanta Pharmaceuticals
- data total pendapatan lan volume dodolan:
ENTA - Total pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan Enanta Pharmaceuticals Inc.|ENTA - Multiplikator P/S|Multiplikator forward rega marang pendapatan Enanta Pharmaceuticals, Inc|ENTA - Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur
Analisis fundamental perusahaan:Enanta (ENTA)
Produk sing diprodhuksi Enanta Pharmaceuticals, Inc

The forward P/S dynamics of Enanta Pharmaceuticals (ENTA) allow for a correlation between the company's market value and expected sales volume, considering the business support provided by royalties during the development of new antiviral agents. This indicator is calculated as the ratio of market capitalization to projected revenue, determining the degree of overpayment for the asset and helping investors identify optimal entry points based on consensus estimates.

Pesaing wigati

Multiplikator Forward P/S GILD (Gilead)|CDTX - Multiplikator forward rega marang pendapatan|NVAX - Rasio rega marang prakiraan pendapatan|CVAC - Multiplikator Forward P/S|Valneva (VALN) - Rasio rega marang prakiraan pendapatan|Vir Biotechnology - Rega forward marang dodolan|SIGA (SIGA Technologies Inc) - Multiplikator Forward P/S|EBS - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan AVIR (Atea Pharmaceuticals)|Rasio rega marang prakiraan pendapatan IVVD (Invivyd Corp)|Inovio - Multiplikator forward rega marang pendapatan|HilleVax - Rasio rega marang prakiraan pendapatan|KLRS - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan DYAI (dyadic.com)|NNVC: Multiplikator Forward P/S|Talphera (TLPH) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Cocrystal Pharma|Multiplikator Forward P/S trawspharma.com|Multiplikator Forward P/S DWTX|Rasio rega marang pendapatan sing dikarepake QLGN|Multiplikator Forward P/S ALVR (AlloVir, Inc.)|VBI Vaccines Inc. (VBIV) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Virios Therapeutics - Multiplikator Forward P/S|VXRT: Rasio rega marang prakiraan pendapatan